TESARO, Inc. (TSRO) PT Set at $190.00 by Credit Suisse Group
TESARO, Inc. (NASDAQ:TSRO) has been given a $190.00 price target by equities research analysts at Credit Suisse Group in a research note issued on Friday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s target price would suggest a potential upside of 74.23% from the company’s current price.
A number of other brokerages have also weighed in on TSRO. Citigroup Inc. reiterated a “buy” rating and issued a $216.00 price target (down previously from $232.00) on shares of TESARO in a report on Saturday, April 22nd. Cowen and Company reiterated a “market perform” rating and issued a $145.00 price target on shares of TESARO in a report on Sunday, April 23rd. FBR & Co decreased their price target on shares of TESARO from $202.00 to $200.00 and set a “mkt perform” rating on the stock in a report on Wednesday, May 10th. Jefferies Group LLC reiterated a “hold” rating on shares of TESARO in a report on Wednesday, May 10th. Finally, Cann reiterated an “outperform” rating on shares of TESARO in a report on Wednesday, May 24th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $173.47.
TESARO (NASDAQ:TSRO) opened at 109.05 on Friday. The company has a 50-day moving average price of $126.76 and a 200-day moving average price of $148.14. TESARO has a 12-month low of $83.26 and a 12-month high of $192.94. The firm’s market capitalization is $5.91 billion.
TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by $0.30. The firm had revenue of $29.50 million during the quarter, compared to analysts’ expectations of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The firm’s revenue was down 17.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.28) earnings per share. On average, analysts predict that TESARO will post ($8.68) earnings per share for the current year.
WARNING: This piece was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/18/tesaro-inc-tsro-pt-set-at-190-00-by-credit-suisse-group.html.
In other TESARO news, VP Edward C. English sold 8,500 shares of the business’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total value of $1,178,525.00. Following the transaction, the vice president now owns 5,396 shares in the company, valued at approximately $748,155.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 40.50% of the company’s stock.
A number of institutional investors have recently modified their holdings of TSRO. Botty Investors LLC purchased a new position in shares of TESARO during the second quarter worth approximately $140,000. Nordea Investment Management AB purchased a new position in shares of TESARO during the second quarter worth approximately $167,000. Meeder Asset Management Inc. purchased a new position in shares of TESARO during the first quarter worth approximately $177,000. Oppenheimer Asset Management Inc. raised its position in shares of TESARO by 3,042.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,430 shares in the last quarter. Finally, BB&T Securities LLC purchased a new position in shares of TESARO during the second quarter worth approximately $222,000.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.